Drug intelligence / Profile preview

yttrium-90 (Yunke Pharmaceutical)

Development stage
Unknown
Lead developer
Chengdu Yunke Pharmaceutical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous, Intra-arterial
01

Overview

Yttrium-90 (90Y) is a medical radionuclide produced by Yunke Pharmaceutical (a subsidiary of China Isotope & Radiation Corporation) for use in therapeutic radiopharmaceuticals. As a high-energy beta-emitter with a physical half-life of approximately 64.1 hours, Yttrium-90 is utilized in targeted radionuclide therapy (TRT) to deliver localized ionizing radiation to malignant tissues. It is commonly conjugated to carriers such as glass or resin microspheres for selective internal radiation therapy (SIRT) of liver cancer, or to monoclonal antibodies for the treatment of non-Hodgkin lymphoma. Yunke Pharmaceutical lists Yttrium-90 as one of its core medical isotopes, supporting its industrial layout in the production and supply of radionuclides for oncology and other therapeutic applications.

Other names
Yttrium-90 productYttrium90 productYttrium 90 product钇[90Y]
02

Targets

DNA

Beyond the preview

Go deeper on yttrium-90 (Yunke Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on yttrium-90 (Yunke Pharmaceutical).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call